TY - JOUR
T1 - 1,2,4-Oxadiazole topsentin analogs as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A
AU - Parrino, Barbara
AU - Carbone, Daniela
AU - Cascioferro, Stella
AU - Pecoraro, Camilla
AU - Giovannetti, Elisa
AU - Deng, Dongmei
AU - Di Sarno, Veronica
AU - Musella, Simona
AU - Auriemma, Giulia
AU - Cusimano, Maria Grazia
AU - Schillaci, Domenico
AU - Cirrincione, Girolamo
AU - Diana, Patrizia
N1 - Funding Information: This research was funded by European Union 2014–2020 PON Ricerca e Innovazione grant from the Italian Ministry of Education, University and Research , entitled “PROGEMA—Processi Green per l’Estrazione di Principi Attivi e la Depurazione di Matrici di Scarto e Non” ( ARS01_00432 ) in favour of P.D. Funding Information: This research was funded by European Union 2014?2020 PON Ricerca e Innovazione grant from the Italian Ministry of Education, University and Research, entitled ?PROGEMA?Processi Green per l'Estrazione di Principi Attivi e la Depurazione di Matrici di Scarto e Non? (ARS01_00432) in favour of P.D. Publisher Copyright: © 2020 Elsevier Masson SAS
PY - 2021/1/1
Y1 - 2021/1/1
N2 - The inhibition or prevention of biofilm formation represents an emerging strategy in the war against antibiotic resistance, interfering with key players in bacterial virulence. This approach includes the inhibition of the catalytic activity of transpeptidase sortase A (Srt A), a membrane enzyme responsible for covalently attaching a wide variety of adhesive matrix molecules to the peptidoglycan cell wall in Gram-positive strains. A new series of seventeen 1,2,4-oxadiazole derivatives was efficiently synthesized and screened as potential new anti-virulence agents. The ability of inhibiting biofilm formation was evaluated against both Gram-positive and Gram-negative pathogens. Remarkably, all these compounds inhibited S. aureus and/or P. aeruginosa biofilm formation in a dose dependent manner, with 50% biofilm inhibitory concentrations (BIC50s) below 10 μM for the most active compounds. Inhibition of SrtA was validated as one of the possible mechanisms of action of these new 1,2,4-oxadiazole derivatives, in the tested Gram-positive pathogen, using a specific enzymatic assay for a recombinant S. aureus SrtA. The three most active compounds, eliciting BIC50 values for S. aureus ATCC 25923 between 0.7 and 9.7 μM, showed a good activity toward the enzyme eliciting IC50 values ranging from 2.2 to 10.4 μM.
AB - The inhibition or prevention of biofilm formation represents an emerging strategy in the war against antibiotic resistance, interfering with key players in bacterial virulence. This approach includes the inhibition of the catalytic activity of transpeptidase sortase A (Srt A), a membrane enzyme responsible for covalently attaching a wide variety of adhesive matrix molecules to the peptidoglycan cell wall in Gram-positive strains. A new series of seventeen 1,2,4-oxadiazole derivatives was efficiently synthesized and screened as potential new anti-virulence agents. The ability of inhibiting biofilm formation was evaluated against both Gram-positive and Gram-negative pathogens. Remarkably, all these compounds inhibited S. aureus and/or P. aeruginosa biofilm formation in a dose dependent manner, with 50% biofilm inhibitory concentrations (BIC50s) below 10 μM for the most active compounds. Inhibition of SrtA was validated as one of the possible mechanisms of action of these new 1,2,4-oxadiazole derivatives, in the tested Gram-positive pathogen, using a specific enzymatic assay for a recombinant S. aureus SrtA. The three most active compounds, eliciting BIC50 values for S. aureus ATCC 25923 between 0.7 and 9.7 μM, showed a good activity toward the enzyme eliciting IC50 values ranging from 2.2 to 10.4 μM.
KW - 1,2,4-Oxadiazoles
KW - Anti-virulence agents
KW - Antibiofilm activity
KW - Marine alkaloids
KW - Sortase A inhibitors
KW - Topsentin analogs
UR - http://www.scopus.com/inward/record.url?scp=85092062968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092062968&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85092062968&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/33035921
U2 - https://doi.org/10.1016/j.ejmech.2020.112892
DO - https://doi.org/10.1016/j.ejmech.2020.112892
M3 - Article
C2 - 33035921
SN - 0223-5234
VL - 209
SP - 1
EP - 11
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 112892
ER -